Cantargia Patent Granted in Australia

Cantargia AB (”Cantargia”) (STO:CANTA) has obtained a granted patent in Australia concerning IL1RAP as a target molecule for antibody based therapy and diagnostic methods of leukemia.

Based on this grant, Cantargia´s method for treatment of leukemia has protection within Europe, South Africa and Australia. The corresponding application is currently under review by authorities in e.g. USA, Japan and China.

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160202006777/en/